All In Biotech

Drug Trial Radar · NCT02562482

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Nov 18, 2015

Primary completion

Mar 6, 2018

Study completion Mar 6, 2018

Sponsor

Sponsor type
NIH
First posted
Sep 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and immunogenicity of a 2-injection vaccine Chikungunya virus (CHIKV) virus-like particle vaccine (CHIKV VLP) in healthy adults.

Conditions

  • Chikungunya Virus Infection

Interventions

  • VRC-CHKVLP059-00-VPBiological

    VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).

  • VRC-PBSPLA043-00-VPOther

    VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any InjectionTime frame: 7 days after any injection
  2. Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Any InjectionTime frame: 7 days after any injection
  3. Number of Subjects With an Abnormal Laboratory ResultTime frame: 4 weeks after last injection
  4. Number of Subjects Reporting Unsolicited Adverse Events (AEs)Time frame: Through study completion, an average of 72 weeks after first injection
  5. Number of Subjects Reporting Serious Adverse Events (SAEs)Time frame: Through study completion, an average of 72 weeks after first injection
  6. Number of Subjects With Confirmed Chikungunya Virus (CHIKV) Infection EventsTime frame: Through study completion, an average of 72 weeks after first injection

Locations

6 sites in 5 countries. Site status is shown where the registry gives one.

  • Instituto Dermatológico y Cirugía de Piel

    Santo Domingo, Dominican Republic

  • University Hospital of Pointe-à-Pitre

    Pointe-à-Pitre, Guadeloupe

  • Centres GHESKIO

    Port-au-Prince, Haiti

  • Centre Hospitalier Universitaire (CHU), Martinique

    Fort-de-France, Martinique

  • San Juan Hospital, Research Unit

    Rio Piedras, Puerto Rico

  • Puerto Rico Clinical and Translational Research Consortium

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.